EWEdwards Lifesciences
$85.21+14% 1Y
$85.21
$72.6552 weeks$93.68
Latest close: back above its 200-day averageOct 9, 2026what changed →
EW in its own filings
EW's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
365
Events found in the filings · across 2,612 filings · the record starts in 2000
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 28, 2026
Most recent filing · Form 8-K
- Record starts
- May 15, 2000
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 29, 2026
- Restatement admitted (non-reliance)historical
- 2012-02-27
- Delisting notice / listing-rule failurehistorical
- 2008-11-10
- Material impairmenthistorical
- 2006-12-05
- SEC comment-letter activity22 occurrences
- 2022-11-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 28, 2026The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.Director or officer change · Form 8-K
- Jul 23, 2026Edwards Lifesciences Corporation.Earnings release · press release
- May 8, 2026Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term …Director or officer change · Form 8-K
- May 4, 2026On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.Director or officer change · Form 8-K
- Apr 23, 2026Edwards Lifesciences Corporation.Earnings release · press release
- Feb 10, 2026Edwards Lifesciences Corporation.Earnings release · press release
- Oct 30, 2025On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026.Director or officer change · Form 8-K
- Oct 30, 2025Edwards Lifesciences Corporation.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Devices
The closest names by size in the same industry